The objective of this study is to evaluate whether antifungal prophylaxis with isavuconazole can reduce the incidence of SARS-CoV-2-associated invasive aspergillosis in patients in the ICU (intensive care unit) with severe COVID-19 infection. The investigators will perform an interventional, double-blinded, randomized-controlled, multi-center study in patients with severe COVID-19 infection admitted to the ICU. Patients will be randomized to the isavuconazole prophylaxis plus standard of care (SOC) group or the placebo plus SOC group. Participants will receive isavuconazole or placebo for up to 28 days or until discharge from the hospital (whichever occurs first).
Adult patients with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 (COVID-19) infection
without a diagnosis of invasive aspergillosis who are hospitalized in the ICU are eligible
for inclusion in this study and will be randomized to the isavuconazole plus standard of care
(SOC) group or placebo plus SOC group.
If randomized to the isavuconazole group, participants will receive intravenous
isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous
isavuconazonium sulfate 372 mg once daily for up to 28 days. If randomized to the placebo
group, participants will receive intravenous placebo every 8 hours for 6 doses followed by
once daily for up to 28 days. Both groups will receive the usual SOC.
Following randomized to the two treatment arms, participants will be screened for invasive
aspergillosis with thrice weekly fungal cultures from tracheal aspirate (TA) secretions or
thrice weekly serum galactomannan (GM) testing (if TA unable to be performed,
contraindicated, or participant is not intubated). If invasive aspergillosis or other
invasive fungal infection is detected, antifungal therapy will be initiated (if the
participant is in the placebo arm) or modified if needed (if the participant is in the
isavuconazole arm).
Drug: Isavuconazonium Injection [Cresemba]
Intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous isavuconazonium sulfate 372 mg once daily for up to 28 days
Other Name: Array
Drug: Placebo
Intravenous placebo every 8 hours for 6 doses followed by intravenous placebo once daily for up to 28 days
Inclusion Criteria:
- Written informed consent obtained from the patient or his/her legally authorized
person.
- Adult patient (> 18 years).
- PCR-confirmed SARS-CoV-2 based on nasopharyngeal swab (NPS), oropharyngeal swab (OPS),
tracheal aspirate (TA), bronchial aspirate (BA), or bronchoalveolar lavage fluid
(BALF) within 14 days prior to ICU admission or within 72 hours following ICU
admission.
- Radiographic imaging consistent with SARS-CoV-2 infection (e.g. atypical pneumonia,
organizing pneumonia, ground glass opacities) or acute respiratory distress syndrome
(ARDS) within 7 days of diagnosis of SARS-CoV-2 infection.
- A negative pregnancy test in women of child-bearing age.
- If a woman is of child-bearing age, she must be willing to use an effective method of
contraception for 28 days after the final dose of isavuconazole per manufacturer
instructions
Exclusion Criteria:
- Anticipated transfer to another medical center that is not a study site within hours
of admission to the ICU.
- Pregnancy based on a positive human chorionic gonadotropin (HCG) test from serum or
urine.
- Patient who is breastfeeding and unable to discontinue breastfeeding while taking the
study drug.
- Patients with a diagnosis of invasive aspergillosis/detection of Aspergillus spp. by
culture from sputum, TA, BA, or BALF or positive GM from serum or BALF at time of
screening or randomization.
- History of invasive aspergillosis within the prior six months.
- Patients with a known intolerance or hypersensitivity to isavuconazole or other azole
agents.
- History of familial short QT syndrome.
- Patients that are being treated with mold-active antifungal agents for invasive
aspergillosis or another invasive fungal infection.
- Patients with severe hepatic impairment or liver cirrhosis (Child C) should be
excluded from the study unless the treating physicians feel the benefits of treatment
outweigh the risks.
- Treatment with Lopinavir/ritonavir for HIV infection.
- Prohibited Medications
- Co-administration with a strong CYP3A4 inhibitor or high-dose ritonavir as they may
alter the plasma concentration of isavuconazole.
- Co-administration with a strong CYP3A4 inducer such as rifampin, carbamazepine, St.
John's wort, or long acting barbiturates.
University of California Irvine
Orange, California, United States
University of California Davis
Sacramento, California, United States
University of California San Diego
San Diego, California, United States